GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Blood, American Society of Hematology, Vol. 129, No. 3 ( 2017-01-19), p. 307-318
    Abstract: Human HSCs show higher tonic signaling activity in multiple pathways than MPPs. Growth factor–activated AKT and β-catenin in human HSCs regulate their survival and mitogenesis.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2017
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Nature Biotechnology, Springer Science and Business Media LLC, Vol. 30, No. 9 ( 2012-09), p. 858-867
    Type of Medium: Online Resource
    ISSN: 1087-0156 , 1546-1696
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2012
    detail.hit.zdb_id: 1494943-X
    detail.hit.zdb_id: 1311932-1
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 3
    Online Resource
    Online Resource
    American Society of Hematology ; 2012
    In:  Blood Vol. 120, No. 21 ( 2012-11-16), p. 1411-1411
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 1411-1411
    Abstract: Abstract 1411 Background: Currently available indicators of risk stratification for acute myeloid leukemia (AML) approximate a patient's true prognosis (Rubnitz, J.E., et al., Lancet Oncol, 2010). While signaling networks are central to biological systems they do not lend themselves to easy characterization. As such, network characteristics are not incorporated into risk stratification. There exists a need for computational techniques that enable elucidation of a patient's global signaling state. Flow cytometry is an essential tool for classifying AML surface markers by surface marker expression. Previous work has shown that intracellular signaling responses can be predictive of clinical outcome (Irish et al., Cell 2004; Kornblau et al., Clin. Cancer Res. 2010, Kornblau et al. Blood Cancer J 2011). We hypothesized that there may exist additional layers of information in both cell phenotypes and signaling responses which were not recognized in the low-parameter systems used in these studies, and which, upon characterization, may yield prognostic benefit. Methods: 31-parameter single cell mass cytometry was used to measure the simultaneous co-expression of 16 surface markers and 15 intracellular signaling epitopes in pediatric AML diagnosis bone marrow samples (n=15) and healthy adult bone marrow controls (n=3). Signaling dynamics were measured under 18 stimulation conditions including cytokines and small molecule kinase inhibitors. Single cell resolution enables statistical extraction of correlative relationships which exist among the measured variables. Network inference elucidated the regulatory signaling structure in each patient (Sachs et al. Science 2005, Itani et al. JMLR 2008), and a statistical tool called a decision tree was used to predict the patient's relapse status (Figure 1). Results: The analysis selects network features predictive of clinical outcome, here, relapse status. Of the network edges with a strong statistical signal, the most informative were the relationships between pS6 and pSTAT1, pAKT and cleaved Caspase3, pAMPK and pRb, pRb and pP38, pAMPK and pErk and pCREB and pCbl. Despite the small dataset size, the decision tree correctly classified 〉 85% of the patients, an improvement over a random model which returns 50% accuracy. (The predicted value was excluded from training to avoid “memorization” by the classification model). For a small subset of the patients (3) who relapsed, paired relapse samples were also available. Strikingly, of the network features which consistently differed between the diagnostic sample and its paired relapse counterpart, two overlapped with those found to have predictive information in the above: pAMPK – pRb and pRb – pP38. These results implicate a coordination of metabolism, cell cycle and survival Conclusions: Statistical classification typically relies on large numbers of profiled samples; thus the ability to predict relapse status from diagnostic samples in this small pilot study is a strong indication of the utility of this approach. Predictive accuracy relied on network features and was not achieved using univariate measurements alone. Furthermore, the features extracted by the predictive model determine which correlations help reveal the prognostic fate of a tumor at diagnosis, potentially providing mechanistic insight. These correlative relationships corroborate the roles of metabolism, survival and cell cycle in AML. The application of 31-parameter mass cytometry at the single cell level provided a level of detail that enabled characterization of signaling relationships at high resolution. This proof of principle study will inform future studies of AML signaling networks and prognostic biomarkers. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 4
    In: Blood, American Society of Hematology, Vol. 116, No. 21 ( 2010-11-19), p. 3160-3160
    Abstract: Abstract 3160 While oncogene addiction is a well-documented phenomenon, the molecular mechanisms by which oncogene withdrawal triggers cell death are poorly understood. Interrogation of this phenomenon in a manipulatable murine model, coupled to concomitant analysis of human AML samples, could elucidate this phenomenon for therapeutic applications. In order to decipher these molecular mechanisms, we employ a murine model harboring a tetracycline repressible, activated NRAS (NRASG12V) transgene along with an MLL/AF9 transgene to induce AML development. Primary leukemia cells are then transplanted into SCID mice and, upon development of full-blown leukemia, NRASG12V transgene expression is repressed with doxycycline. Previous work has shown that repression of NRASG12V in this model leads to widespread apoptosis of the leukemia cells (Kim et al. Blood 2009). To analyze the kinetics of this response, we found that the tumor burden, as assayed by the white blood cell (WBC) count, declines by 60 hours of doxycycline treatment. NRASG12V message levels are undetectable by 12 hours while protein expression begins to decline after 48 hours. To dissect the signaling network directing the apoptotic response, the phosphorylation status of critical signaling intermediates was analyzed by flow cytometry at time points from 48–96 hours post-doxycycline treatment. This analysis revealed numerous modifications in known NRAS effectors including loss of phosphoErk1/2, phosphoSTAT3, and phosphop38. These alterations correlate with immunophenotypic cell surfaces markers. Whereas leukemia cells expressing mature myeloid markers (Mac1+) do not exhibit alterations in any of the phosphoproteins tested, only Mac1- leukemia cells show meaningful changes in RAS-activated signaling molecules. Whether mouse leukemic stem cells reside in the Mac1+ fraction or in the less differentiated subpopulation remains unclear. These findings suggest that subpopulations of leukemia cells exhibit differential vulnerabilities to oncogene addiction. Furthermore, these studies also reveal that oncogene withdrawal leads to a reduction of the Mac1+Gr1- population and an enrichment of the Mac1-Gr1- and Mac1+Gr1+ populations. Therefore, in addition to effecting apoptosis, oncogene withdrawal leads to alterations in the differentiation status of the leukemia, which could alter the self-renewal capacity of these cells. Using these results, we have designed an extensive antibody panel and are currently using a CyTOF mass spectrometer, a new technology that allows us to perform 30 dimensional measurements to profile immunophenotypic markers and phosphoprotein states with single cell resolution. Simultaneous, high-dimensional single cell profiling of signaling states enables integrative network analysis of these data and as such will allow us to discern pathway dependencies and regulatory relationships that traditional low dimensional flow cytometry cannot (Sachs et al. Science 2005, Sachs et al. IEEE Eng Med Biol Soc 2009). This approach will provide a novel and powerful method to elucidate the critical pathways and leukemic subpopulations that define the response to oncogene withdrawal. Furthermore, these findings will be compared to a concomitant study of 30-dimensional measurements of human AML samples which could facilitate harnessing the oncogene addiction phenomenon in therapeutic applications. Disclosures: No relevant conflicts of interest to declare.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2010
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 5
    In: Science, American Association for the Advancement of Science (AAAS), Vol. 332, No. 6030 ( 2011-05-06), p. 687-696
    Abstract: Flow cytometry is an essential tool for dissecting the functional complexity of hematopoiesis. We used single-cell “mass cytometry” to examine healthy human bone marrow, measuring 34 parameters simultaneously in single cells (binding of 31 antibodies, viability, DNA content, and relative cell size). The signaling behavior of cell subsets spanning a defined hematopoietic hierarchy was monitored with 18 simultaneous markers of functional signaling states perturbed by a set of ex vivo stimuli and inhibitors. The data set allowed for an algorithmically driven assembly of related cell types defined by surface antigen expression, providing a superimposable map of cell signaling responses in combination with drug inhibition. Visualized in this manner, the analysis revealed previously unappreciated instances of both precise signaling responses that were bounded within conventionally defined cell subsets and more continuous phosphorylation responses that crossed cell population boundaries in unexpected manners yet tracked closely with cellular phenotype. Collectively, such single-cell analyses provide system-wide views of immune signaling in healthy human hematopoiesis, against which drug action and disease can be compared for mechanistic studies and pharmacologic intervention.
    Type of Medium: Online Resource
    ISSN: 0036-8075 , 1095-9203
    RVK:
    RVK:
    Language: English
    Publisher: American Association for the Advancement of Science (AAAS)
    Publication Date: 2011
    detail.hit.zdb_id: 128410-1
    detail.hit.zdb_id: 2066996-3
    detail.hit.zdb_id: 2060783-0
    SSG: 11
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 6
    Online Resource
    Online Resource
    Springer Science and Business Media LLC ; 2011
    In:  Nature Biotechnology Vol. 29, No. 10 ( 2011-10), p. 886-891
    In: Nature Biotechnology, Springer Science and Business Media LLC, Vol. 29, No. 10 ( 2011-10), p. 886-891
    Type of Medium: Online Resource
    ISSN: 1087-0156 , 1546-1696
    Language: English
    Publisher: Springer Science and Business Media LLC
    Publication Date: 2011
    detail.hit.zdb_id: 1494943-X
    detail.hit.zdb_id: 1311932-1
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 7
    In: Cytometry Part A, Wiley, Vol. 83A, No. 5 ( 2013-05), p. 483-494
    Type of Medium: Online Resource
    ISSN: 1552-4922
    URL: Issue
    Language: English
    Publisher: Wiley
    Publication Date: 2013
    detail.hit.zdb_id: 2180639-1
    SSG: 12
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 8
    In: Blood, American Society of Hematology, Vol. 122, No. 21 ( 2013-11-15), p. 819-819
    Abstract: Hyperactivated Ras-pathways serve as oncogenic drivers in multiple human tumors including acute myelogenous leukemia (AML) (Ahearn et al. Nat Rev Mol Cell Biol 2011). The specific functions of these pathways in AML are unclear, thwarting the rational application of targeted therapeutics. Recently, we have shown that NRASG12V–activated signaling pathways are critical to leukemia stem cell maintenance (Sachs et al. submitted). To elucidate which Ras-activated signaling molecules mediate self-renewal in AML, we employed a murine model that harbors Mll-AF9 and a tetracycline repressible, activated NRAS (NRASG12V) and develops AML (Kim et al. Blood 2009). Primary leukemia cells were treated with therapeutic agents targeting Ras-activated signaling pathways. We used PD325901 to inhibit the Mek-Erk pathway, GDC0941 to inhibit the Pi3k pathway, and RAD001 to inhibit the mTor pathway. Using MTS assays, we identified the IC50 dose for each of these agents. Inhibitor-treated leukemia cells were submitted for RNA sequencing in order to investigate the effects of these agents on leukemia gene expression. Previously, we identified a list of NRASG12V responsive genes in our model. In these studies, we identified that PD325901-treatment most closely recapitulates the effect of NRASG12V inhibition on this comprehensive list of RAS-responsive genes. However, when we study the effects of these inhibitors on the subset of RAS-responsive genes that mediate leukemia self-renewal, we find that both PD325901 and RAD001 independently recapitulate the effects of NRASG12V withdrawal on this subset of genes implicating the Mek and mTor pathways in leukemia self renewal. Next, we treated primary leukemia cells with the IC50 dose of each drug and plated them in colony forming assays. We found that Mek or mTor inhibition, but not Pi3k inhibition, abrogated secondary colony formation corroborating our gene expression analyses and showing that, at doses that have equivalent effects on cell growth, only the Mek and mTor pathways are important for leukemia cell stem cell maintenance. These studies provide potential targets for leukemia stem cell-specific therapies. Disclosures: Sachs: Silicon Valley Biosystems: Consultancy. Bendall:DVS Sciences: Consultancy. Nolan:SAB for DVS Sciences and Nodality: Chairman Other; Cell Signalling Technologies and Becton Dickenson, Inc: Consultancy. Largaespada:Discovery Genomics, Inc: Consultancy, Share Holder Other; NeoClone Biotechnology, Inc: Consultancy, Share Holder, Share Holder Other.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2013
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 9
    In: Blood, American Society of Hematology, Vol. 124, No. 22 ( 2014-11-20), p. 3274-3283
    Abstract: NRAS G12V maintains leukemia self-renewal in a genetically engineered murine model of AML. NRAS G12V differentially regulates transcription and signaling among leukemic subpopulations.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2014
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 10
    In: Blood, American Society of Hematology, Vol. 120, No. 21 ( 2012-11-16), p. 5116-5116
    Abstract: Abstract 5116 RAS is a known oncogene in AML (Schubbert et al. Nat Rev Cancer 2007, Bowen et al. Blood 2006), however the specific effects of targeting RAS-activated pathways on AML physiology are unclear. NRASG12V transgene repression in an NRASG12V/Mll/AF9 transgenic murine AML model leads to apoptosis and disease remission (Kim et al. Blood 2009). To better understand possibilities for and implications of therapeutic targeting of RAS-activated pathways, we inactivate NRASG12V in this mouse model and characterize the subsequent signaling and transcriptional response. We profiled signaling intermediates and markers of apoptosis and cell cycle using mass cytometry, a next-generation flow cytometry technology, which simultaneously measured the levels of 32 antibody-labeled proteins in single cells. These analyses revealed specific signaling changes that varied with the surface immunophenotype of the AML cells and highlighted relevant RAS-directed signaling pathways. Parallel RNA sequencing and gene expression microarrays revealed that NRASG12V-expressing cells express hematopoietic self-renewal genes and repression of NRASG12V leads to loss of this program. Importantly, the NRASG12V-dependent gene expression program mimics the Mll/AF9-determined, Myb-mediated self-renewal program reported by Zuber et al. (Zuber et al. Genes Dev 2011). These data suggest a novel role for RAS in AML self-renewal capacity by maintaining the Mll/AF9-mediated self-renewal program. Furthermore, inhibition of the PI3K-mTOR pathway decreases viability, in vitro colony formation, and recapitulates the effects of NRASG12V inactivation on self renewal-associated genes, implicating this pathway as the mediator of RAS-directed leukemia self renewal capacity. These data provide rationale for therapeutic targeting of leukemia stem cells via PI3K-mTOR pathway inhibition and for using this mouse model as a tool to test such therapeutic approaches. Since a variety of AML-specific genetic mutations lead to perturbations in RAS signaling, these results may be generalizable to AML with a broader range of mutations. Figure: NRAS-dependent gene expression signature recapitulates Mll/AF9 gene expression signature. Figure:. NRAS-dependent gene expression signature recapitulates Mll/AF9 gene expression signature. Disclosures: Largaespada: Discovery Genomics, Inc. : Consultancy, Equity Ownership; NeoClone Biotechnology, Inc. : Consultancy, Equity Ownership.
    Type of Medium: Online Resource
    ISSN: 0006-4971 , 1528-0020
    RVK:
    RVK:
    Language: English
    Publisher: American Society of Hematology
    Publication Date: 2012
    detail.hit.zdb_id: 1468538-3
    detail.hit.zdb_id: 80069-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...